|本期目录/Table of Contents|

[1]刘雪娇,盛伟利,丁艳艳,等.特发性肺纤维化急性加重患者预后危险因素及意义[J].中华肺部疾病杂志,2022,(02):212-214.[doi:10.3877/cma.j.issn.1674-6902.2022.02.017]
点击复制

特发性肺纤维化急性加重患者预后危险因素及意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年02期
页码:
212-214
栏目:
临床研究
出版日期:
2022-04-20

文章信息/Info

Title:
-
作者:
刘雪娇; 盛伟利; 丁艳艳; 尹凤先
102600 北京,首都医科大学大兴教学医院呼吸与危重症医学科
Author(s):
-
关键词:
特发性肺纤维化;  急性加重;  危险因素
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.02.017
摘要:
目的 分析特发性肺纤维化急性加重(AE-IPF)患者住院期间预后的危险因素。方法 选择2013年1月至2020年12月于首都医科大学大兴教学医院呼吸内科确诊为AE-IPF的住院患者99例为对象,采用单因素分析及多因素非条件Logistic回归分析住院期间预后的危险因素。以回归分析有统计学意义指标的中位数为截点值(Cutoff值)分别分组,计算组间生存率。结果 单因素分析显示,AE-IPF患者住院期间预后危险因素包括:1年内因AE住院次数(P=0.001)、体温(P=0.005)、血D-二聚体(P=0.012)、血白蛋白(P=0.006)、血乳酸脱氢酶(P=0.001)、氧合指数(P=0.002)与AE-IPF患者住院期间死亡相关。多因素Logistic回归分析显示,体温(OR=22.158,P=0.042)、1年内因AE住院次数(OR=2.474,P=0.011)、血白蛋白(OR=0.819,P=0.026)、血乳酸脱氢酶(OR=1.011,P=0.049)为AE-IPF患者住院期间预后的危险因素。以体温、血乳酸脱氢酶中位数为截点值分别分组,绘制Kaplan-Meier曲线,组间生存率比较P<0.05。结论 1年内因AE住院次数、体温、血白蛋白及血乳酸脱氢酶,是AE-IPF患者住院期间预后的危险因素。体温、血乳酸脱氢酶对AE-IPF患者住院期间预后有预测意义。
Abstract:
-

参考文献/References:

1 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011,183(6): 788-824.
2 Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline[J]. Am J Respir Crit Care Med, 2015, 192(2): e3-e19.
3 Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 1998, 157(1): 199-203.
4 Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia[J]. Eur Respir J, 2002, 19(2): 275-283.
5 King TJ, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis:relationship between histopathologic features and mortality[J]. Am J Respir Crit Care Med, 2001, 164(6): 1025-1032.
6 Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival[J]. Thorax, 2007, 62(1): 62-66.
7 中华医学会呼吸病学分会间质性肺病学组, 中国医师协会呼吸医师分会间质性肺疾病工作委员会. 特发性肺纤维化急性加重诊断和治疗中国专家共识[J]. 中华医学杂志, 2019, 99(26): 2014-2023.
8 任成山, 钱桂生. 特发性间质性肺炎的现代概念及研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2010, 10(4): 276-284.
9 邱 静, 孙 建, 李万成. 特发性肺纤维化中TGF-β1诱导上皮细胞间质转化作用机制研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(2): 212-214.
10 Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm [J]. Eur Respir J, 2015, 46(2): 512-520.
11 Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials[J]. Respir Med, 2014, 108(2): 376-387.
12 Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials[J]. Respir Res, 2013, 14(1): 73.
13 Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome[J]. Eur Respir J, 2011, 37(2): 356-363.
14 Simon-Blancal V, Freynet O, Nunes H, et al. Acute exacerbation of idiopathic pulmonary fibrosis: Outcome and prognostic factors[J]. Respir, 2012, 83(1): 28-35.
15 Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences[J]. Am J Respir Crit Care Med, 2014, 190(7):773-779.
16 Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study[J]. Chest, 2010, 137(1): 129-137.
17 Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, et al. Prognosis and follow-up of idiopathic pulmonary fibrosis[J]. Med Sci(Basel), 2018, 6(2): 51.
18 Invernizzi R, Molyneaux PL. The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis[J]. Eur Respir Rev, 2019, 28(152): 190045.
19 Weng D, Chen XQ, Qiu H, et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis[J]. Med Inflamm, 2019, 2019: 5160694.
20 Johannson K, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: A proposal[J]. Curr Respir Care Rep, 2013, 2(4): 10.
21 魏丽娟, 庄蝶微, 崔 娜, 等. 特发性肺纤维化生存影响因素分析[J]. 中日友好医院学报, 2015, 29(5): 297-298.
22 秦文婧, 梁 宇, 单远莹, 等. 影响特发性肺纤维化预后的相关因素分析[J]. 中国现代医生, 2016, 54(02): 33-35.
23 Kang HS, Cho KW, Kwon SS, et al. Prognostic significance of Glasgow prognostic score in patients with acute exacerbation of idiopathic pulmonary fibrosis[J]. Respir, 2018, 23(2): 206-212.
24 冷 冬, 李桂芹, 王 颖, 等. 肺纤维化风险预测的临床生物化学模型[J]. 首都医科大学学报, 2019, 40(6): 875-880.
25 Ishikawa G, Acquah SO, Salvatore M, et al. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease[J]. Respir Med, 2017, 128: 78-84.
26 李 燕, 苗立云, 姜涵毅, 等. 特发性肺纤维化预后相关因素的回顾性研究[J]. 中国呼吸与危重监护杂志, 2012, 11(3): 257-261.
27 Isshiki T, Sakamoto S, Kinoshita A, et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study [J]. Respir, 2015, 89(3): 201-207.
28 Hachisu Y, Murata K, Takei K, et al. Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis[J]. Med(Kaunas), 2019, 55(5): 132-143.

备注/Memo

备注/Memo:
基金项目: 北京市科技计划课题项目(Z171100001017243) 通信作者: 尹凤先, Email: feust@sohu.com
更新日期/Last Update: 2022-04-20